A single intrathecal injection of DNA and an asymmetric cationic lipid as lipoplexes ameliorates experimental autoimmune encephalomyelitis

Srikanth Yellayi, Brendan Hilliard, Mustafa Ghazanfar, Akivaga Tsingalia, Michael H. Nantz, Laura Bollinger, Fabian De Kok-Mercado, James G. Hecker

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Intrathecal delivery of gene therapeutics is a route of administration that overcomes several of the limitations that plague current immunosuppressive treatments for autoimmune diseases of the central nervous system (CNS). Here we report intrathecal delivery of small amounts (3 μg) of plasmid DNA that codes for an immunomodulatory fusion protein, OX40-TRAIL, composed of OX40, a tumor necrosis factor receptor, and tumor necrosis factor related apoptosis inducing ligand (TRAIL). This DNA was delivered in a formulated nucleic acid-lipid complex (lipoplexes) with an asymmetric two-chain cationic lipid myristoyl (14:0) and lauroyl (12:1) rosenthal inhibitor-substituted compound (MLRI) formed from the tetraalkylammonium glycerol-based compound N-(1-(2,3-dioleoyloxy)- propyl-N-1-(2-hydroxy)ethyl)-N,N-dimethyl ammonium iodide. Delivery and expression in the CNS of OX40-TRAIL in the mouse prior to onset of experimental autoimmune encephalomyelitis (EAE), an animal model for multiple sclerosis, decreased the severity of clinical disease. We believe this preclinical demonstration of rapid, widespread, and biologically therapeutic nonviral gene delivery to the CNS is important in further development of clinical lipid-based therapeutics for CNS disorders.

Original languageEnglish (US)
Pages (from-to)1980-1984
Number of pages5
JournalMolecular Pharmaceutics
Volume8
Issue number5
DOIs
StatePublished - Oct 3 2011
Externally publishedYes

Fingerprint

Spinal Injections
Autoimmune Experimental Encephalomyelitis
Lipids
Central Nervous System
Tumor Necrosis Factor-alpha
DNA
Apoptosis
OX40 Ligand
Autoimmune Diseases of the Nervous System
Ligands
Plague
Tumor Necrosis Factor Receptors
Central Nervous System Diseases
Therapeutics
Immunosuppressive Agents
Glycerol
Nucleic Acids
Genes
Multiple Sclerosis
Plasmids

Keywords

  • animal model
  • asymmetric lipids
  • CNS gene delivery
  • experimental autoimmune encephalomyelitis

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Molecular Medicine
  • Drug Discovery

Cite this

Yellayi, S., Hilliard, B., Ghazanfar, M., Tsingalia, A., Nantz, M. H., Bollinger, L., ... Hecker, J. G. (2011). A single intrathecal injection of DNA and an asymmetric cationic lipid as lipoplexes ameliorates experimental autoimmune encephalomyelitis. Molecular Pharmaceutics, 8(5), 1980-1984. https://doi.org/10.1021/mp2002413

A single intrathecal injection of DNA and an asymmetric cationic lipid as lipoplexes ameliorates experimental autoimmune encephalomyelitis. / Yellayi, Srikanth; Hilliard, Brendan; Ghazanfar, Mustafa; Tsingalia, Akivaga; Nantz, Michael H.; Bollinger, Laura; De Kok-Mercado, Fabian; Hecker, James G.

In: Molecular Pharmaceutics, Vol. 8, No. 5, 03.10.2011, p. 1980-1984.

Research output: Contribution to journalArticle

Yellayi, S, Hilliard, B, Ghazanfar, M, Tsingalia, A, Nantz, MH, Bollinger, L, De Kok-Mercado, F & Hecker, JG 2011, 'A single intrathecal injection of DNA and an asymmetric cationic lipid as lipoplexes ameliorates experimental autoimmune encephalomyelitis', Molecular Pharmaceutics, vol. 8, no. 5, pp. 1980-1984. https://doi.org/10.1021/mp2002413
Yellayi, Srikanth ; Hilliard, Brendan ; Ghazanfar, Mustafa ; Tsingalia, Akivaga ; Nantz, Michael H. ; Bollinger, Laura ; De Kok-Mercado, Fabian ; Hecker, James G. / A single intrathecal injection of DNA and an asymmetric cationic lipid as lipoplexes ameliorates experimental autoimmune encephalomyelitis. In: Molecular Pharmaceutics. 2011 ; Vol. 8, No. 5. pp. 1980-1984.
@article{40e3636dca8d43ff83c455cb05aed1c0,
title = "A single intrathecal injection of DNA and an asymmetric cationic lipid as lipoplexes ameliorates experimental autoimmune encephalomyelitis",
abstract = "Intrathecal delivery of gene therapeutics is a route of administration that overcomes several of the limitations that plague current immunosuppressive treatments for autoimmune diseases of the central nervous system (CNS). Here we report intrathecal delivery of small amounts (3 μg) of plasmid DNA that codes for an immunomodulatory fusion protein, OX40-TRAIL, composed of OX40, a tumor necrosis factor receptor, and tumor necrosis factor related apoptosis inducing ligand (TRAIL). This DNA was delivered in a formulated nucleic acid-lipid complex (lipoplexes) with an asymmetric two-chain cationic lipid myristoyl (14:0) and lauroyl (12:1) rosenthal inhibitor-substituted compound (MLRI) formed from the tetraalkylammonium glycerol-based compound N-(1-(2,3-dioleoyloxy)- propyl-N-1-(2-hydroxy)ethyl)-N,N-dimethyl ammonium iodide. Delivery and expression in the CNS of OX40-TRAIL in the mouse prior to onset of experimental autoimmune encephalomyelitis (EAE), an animal model for multiple sclerosis, decreased the severity of clinical disease. We believe this preclinical demonstration of rapid, widespread, and biologically therapeutic nonviral gene delivery to the CNS is important in further development of clinical lipid-based therapeutics for CNS disorders.",
keywords = "animal model, asymmetric lipids, CNS gene delivery, experimental autoimmune encephalomyelitis",
author = "Srikanth Yellayi and Brendan Hilliard and Mustafa Ghazanfar and Akivaga Tsingalia and Nantz, {Michael H.} and Laura Bollinger and {De Kok-Mercado}, Fabian and Hecker, {James G.}",
year = "2011",
month = "10",
day = "3",
doi = "10.1021/mp2002413",
language = "English (US)",
volume = "8",
pages = "1980--1984",
journal = "Foodborne Pathogens and Disease",
issn = "1535-3141",
publisher = "American Chemical Society",
number = "5",

}

TY - JOUR

T1 - A single intrathecal injection of DNA and an asymmetric cationic lipid as lipoplexes ameliorates experimental autoimmune encephalomyelitis

AU - Yellayi, Srikanth

AU - Hilliard, Brendan

AU - Ghazanfar, Mustafa

AU - Tsingalia, Akivaga

AU - Nantz, Michael H.

AU - Bollinger, Laura

AU - De Kok-Mercado, Fabian

AU - Hecker, James G.

PY - 2011/10/3

Y1 - 2011/10/3

N2 - Intrathecal delivery of gene therapeutics is a route of administration that overcomes several of the limitations that plague current immunosuppressive treatments for autoimmune diseases of the central nervous system (CNS). Here we report intrathecal delivery of small amounts (3 μg) of plasmid DNA that codes for an immunomodulatory fusion protein, OX40-TRAIL, composed of OX40, a tumor necrosis factor receptor, and tumor necrosis factor related apoptosis inducing ligand (TRAIL). This DNA was delivered in a formulated nucleic acid-lipid complex (lipoplexes) with an asymmetric two-chain cationic lipid myristoyl (14:0) and lauroyl (12:1) rosenthal inhibitor-substituted compound (MLRI) formed from the tetraalkylammonium glycerol-based compound N-(1-(2,3-dioleoyloxy)- propyl-N-1-(2-hydroxy)ethyl)-N,N-dimethyl ammonium iodide. Delivery and expression in the CNS of OX40-TRAIL in the mouse prior to onset of experimental autoimmune encephalomyelitis (EAE), an animal model for multiple sclerosis, decreased the severity of clinical disease. We believe this preclinical demonstration of rapid, widespread, and biologically therapeutic nonviral gene delivery to the CNS is important in further development of clinical lipid-based therapeutics for CNS disorders.

AB - Intrathecal delivery of gene therapeutics is a route of administration that overcomes several of the limitations that plague current immunosuppressive treatments for autoimmune diseases of the central nervous system (CNS). Here we report intrathecal delivery of small amounts (3 μg) of plasmid DNA that codes for an immunomodulatory fusion protein, OX40-TRAIL, composed of OX40, a tumor necrosis factor receptor, and tumor necrosis factor related apoptosis inducing ligand (TRAIL). This DNA was delivered in a formulated nucleic acid-lipid complex (lipoplexes) with an asymmetric two-chain cationic lipid myristoyl (14:0) and lauroyl (12:1) rosenthal inhibitor-substituted compound (MLRI) formed from the tetraalkylammonium glycerol-based compound N-(1-(2,3-dioleoyloxy)- propyl-N-1-(2-hydroxy)ethyl)-N,N-dimethyl ammonium iodide. Delivery and expression in the CNS of OX40-TRAIL in the mouse prior to onset of experimental autoimmune encephalomyelitis (EAE), an animal model for multiple sclerosis, decreased the severity of clinical disease. We believe this preclinical demonstration of rapid, widespread, and biologically therapeutic nonviral gene delivery to the CNS is important in further development of clinical lipid-based therapeutics for CNS disorders.

KW - animal model

KW - asymmetric lipids

KW - CNS gene delivery

KW - experimental autoimmune encephalomyelitis

UR - http://www.scopus.com/inward/record.url?scp=80053521958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053521958&partnerID=8YFLogxK

U2 - 10.1021/mp2002413

DO - 10.1021/mp2002413

M3 - Article

C2 - 21732666

AN - SCOPUS:80053521958

VL - 8

SP - 1980

EP - 1984

JO - Foodborne Pathogens and Disease

JF - Foodborne Pathogens and Disease

SN - 1535-3141

IS - 5

ER -